|
慢性乙型肝炎 肝硬变患者血清可溶性gp130的变化 |
|
子的信号转导[2]。据报道[3,4]sgp130由gp130的膜外段脱落而成,在人血清中的相对分子质量为90 000和110 000,sgp130对上述细胞因子的活性起抑制作用,其机制是sgp130与上述细胞因子和受体的复合物结合后,影响后者与膜gp130结合,从而使信号转导中断。本研究结果表明,CHB、HC患者血清sgp130含量均高于正常,HC又高于CHB,而CHB患者的重度高于中度,中度又高于轻度,故似可认为血清spg130参与了上述疾病的病理过程,并可作为其病情变化的监测指标。 关于CHB、HC患者血清sgp130升高的确切机制尚不清楚,分析可能与此类疾病患者存在明显的免疫机能紊乱以及患者的肝功能异常,致使其对sgp130的廓清减少有关。
作者单位:223001 江苏淮阴,解放军第82医院
参考文献
1 王加林,赵亚平,周玮,等.他巴唑对Graves 病患者血清可溶性gp130的影响.免疫学杂志,1998,14:42-43. 2 Benigni F, Fantuzzi G, Sacco S, et al. Six different cytokines that share GP130 as a receptor subunit, induce serum amyliod A and potentiale the induction of interleukin-6 and the activation of the hyporthalamus-pituitary-adrenal axis by interleukin-1. Blood, 1996, 87:1851-1854. 3 Hammacher A, Simpson RJ, Nice EC. The interleukin-6(IL-6) partial antagonist (Q159E, T162P) IL-6 interacts with the IL-6 receptor and gp130 but fails to induce a stable hexameric receptor complex, J Biolchem, 1996, 271:5464-5473. 4 Narazakim M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood, 1993,82:1120-1126.
上一页 [1] [2] 上一个医学论文: 血清乙型肝炎病毒核酸定量检测与临床关系 下一个医学论文: 外周血单个核细胞与血清中HBV DNA及其变异比较
|
|
|
|
|
|
|